- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Lilly study: 1 in 5 Alzheimer's patients misdiagnosed
May 20, 2013
J.K. WallThe study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare
to pay for use of its brain imaging agent Amyvid.
MoreCanada’s Supreme Court won’t hear Lilly appeal on Zyprexa
May 16, 2013
Bloomberg NewsEli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major
developed countries.
MoreLechleiter's surgery to repair heart goes as planned
May 14, 2013
Bloomberg NewsEli Lilly and Co. CEO John Lechleiter underwent a scheduled surgery Monday for a heart defect, and the repair to the aorta
is functioning as intended, the Indianapolis-based drugmaker said.
MoreLilly stops development on cancer drug after failed study
May 10, 2013
Bloomberg NewsThe drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual
sales by 2018.
MoreIndiana firms lose ground on Fortune 500 list
May 7, 2013
Mason KingFive of the six Hoosier firms that appear in the 2013 rankings slipped from their positions in last year's list of the largest
U.S. companies.
MoreLilly CEO to step down temporarily due to surgery
May 6, 2013
J.K. WallJohn Lechleiter has been suffering from a dilated aorta, Eli Lilly and Co. said Monday. Current CFO Derica Rice will take
his place until later this summer.
MoreBiosciences institute aims for $300M endowment
May 6, 2013
J.K. WallThe effort to launch the Indiana Biosciences Research Institute got $25 million from the Legislature, but the life sciences
institutions backing the effort have set their funding sights much higher.
MoreLilly's sales-force restructuring to affect 1,600-plus
May 6, 2013
J.K. WallLilly will eliminate 1,624 positions from its U.S. sales force in July, according to a notice the company made to state officials.
But some of those workers may be rehired by the firm.
MoreLilly taking hard look at Pfizer's new Viagra strategy
May 6, 2013
Associated PressMajor drugmakers, including Indianapolis-based Eli Lilly and Co., are closely watching Pfizer Inc.'s plan to sell Viagra directly
to consumers. The bold move blows up the drug industry's distribution model.
MoreLilly suing J&J for patent rights in Alzheimer's drug race
April 25, 2013
Bloomberg NewsEli Lilly and Co. is seeking to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay
availability of a potential treatment for Alzheimer’s disease.
MoreEli Lilly's profit shoots up despite lackluster sales
April 24, 2013
IBJ Staff and Associated PressThe Indianapolis pharmaceutical company left its full-year profit forecast unchanged despite a spike in first-quarter earnings.
Revenue fell short of analyst expectations.
MoreLilly on the rise as investors run back to pharma stocks
April 22, 2013
J.K. WallInvestors are gaining confidence in the ability of major drugmakers, including Eli Lilly and Co., to improve their pipelines
of new products. The big pharma firms begin to report first-quarter earnings this week.
MoreLilly's $30.6M tax abatement request clears hurdle
April 18, 2013
IBJ StaffThe pharmaceutical firm has $400 million in projects in the works for its facilities south of downtown. City officials have
advanced its request for tax breaks to a public hearing and final consideration May 1.
MoreLilly seeks $30.6M in tax breaks on downtown projects
April 15, 2013
Mason KingIndianapolis development officials on Wednesday will weigh the 10-year requests from the pharmaceuticals giant related to
a new manufacturing plant and improvements to existing operations downtown.
MoreAnalysts: Lilly faces 'ugly' period until its pipeline produces
April 15, 2013
J.K. WallInvestor smiles about new experimental cancer drugs and an aggressive play for the animal health market in China turned to
frowns after Lilly disclosed deep cuts to its U.S. sales force.
MoreExpected revenue slump spurs Lilly to cut sales force
April 11, 2013
J.K. WallThe Indianapolis pharmaceuticals giant said Thursday that it would lay off hundreds of U.S. sales reps, as it prepares for
the loss of patent protection on two of its best-selling drugs.
MoreTyco: No proof Lilly thieves used security report
April 8, 2013
Associated PressLawyers for a security company being sued in the theft of $60 million worth of pharmaceuticals from an Eli Lilly and Co. warehouse
in Connecticut say there's no proof the thieves used a report it prepared about security weaknesses in the building.
MoreLilly pulls back from proposals lowering takeover barriers
April 6, 2013
Greg AndrewsFortunately, a Lilly takeover looks less likely today than it has in a long time—for both obvious and more subtle reasons.
MoreLilly warehouse thieves had security report, lawsuit says
April 2, 2013
Associated PressA federal lawsuit contends that thieves who broke into an Eli Lilly and Co. warehouse in Connecticut three years ago and stole
more than $60 million worth of drugs obtained a copy of a report that revealed weaknesses in the building's security system.
MoreLilly to spend $180M doubling size of Indy plant
April 2, 2013
The new investment will bring the plant's total price tag to $320 million as the pharmaceutical giant seeks to increase production
of insulin and related products.
MoreJ&J wins OK for first in new class of diabetes drugs
March 31, 2013
Bloomberg NewsJohnson & Johnson, the world’s largest seller of health-care products, won approval for the first in a new family
of diabetes drugs, giving them the edge against rivals including Eli Lilly and Co. that are developing similar medicines.
MoreLilly, Boehringer submit diabetes drug to FDA
March 25, 2013
Associated PressEli Lilly and Co. said Monday that it has submitted a new type 2 diabetes treatment it is developing with German drugmaker
Boehringer Ingelheim to the Food and Drug Administration.
MoreBonuses drive up compensation for Lilly's top brass
March 25, 2013
J.K. WallEli Lilly and Co. granted larger bonuses to its top five executives early this year, which boosted their 2012 compensation
anywhere from 3 percent to 8 percent.
MoreCourt may decide if drugmakers can pay to delay generics
March 25, 2013
Associated PressFederal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors
to delay releasing their cheaper versions of brand-name drugs. They argue these deals deny American consumers, usually for
years, steep price declines.
MoreProfits at center of biosimilars debate
March 18, 2013
J.K. WallHouse Bill 1315, which is scheduled for a Senate floor hearing on Monday, would require pharmacists to check with a patient’s
physician before automatically substituting a generic version of a biotech drug for a brand-name version.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
First, the Athenaeum is going to have to get past the hurdle with the Lockerbie residents and the agreement that the parcel would be residential. Second, and in my opinion, this prime piece of property should include parking, PLUS, a black box theater(s), some market rate and affordable artist housing and a plan to renovate and reconfigure the second story theater. I would negotiate to add the DeHaan property surface parking lot into the development mix, place a one story surface parking garage on the DeHaan lot on the street level (for the Dehaan tenants use during the daytime) and add a second story to the garage that would become an addition to the current second story theater and then change the direction of the theater by moving the stage across the alley and on top of the DeHaan lot parking. You can add all the stage elements that are currently missing from the Athenaeum stage to make it more attractive for use by Ballet, Opera and traveling productions. Plus, the theater changes would probably help solve some of the soundproofing issues. Alas,it does not seem to be a part of the strategic plan to conduct a study to determine best use of the property. Seems like the current plan is a quick and easy move that ignores the property best use/potential and any strategic property planning for the effect on future generations.
I recall that MSA's pilings are still in the ground and hard to remove. It’s not likely any proposal will include significant underground construction/parking because of this. Start adding 2 floors of retail, 8 floors of parking and 5-10 floors of possible hotel, and/or 10-20 floors of residential, and you are at 30 floors already with possible expansion of all the uses. But then again I could be wrong.
Accoriding to their website there is no deadline to the Do Not Call list. What is this article referring to??
On what planet are they entitled to this largesse from the stockholders? These people make multi-million dollar salaries: Pay for your own personal travel.
It matters because they're already paid enormously fat salaries: Pay for your own personal travel. Being "taxed on it" isn't a valid excuse--so what? They're still being gifted a raft of luxury perks from somebody else's money on top of an enormous, lavish salary.